
EquitySector - HealthcareVery High Risk
Direct
NAV (05-Feb-26)
Returns (Since Inception)
Fund Size
₹297 Cr
Expense Ratio
0.65%
ISIN
INF194KB1KF5
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Nov 2025
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-6.40%
— (Cat Avg.)
| Equity | ₹280.74 Cr | 94.46% |
| Others | ₹16.45 Cr | 5.54% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹25.8 Cr | 8.68% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹23.24 Cr | 7.82% |
| Divi's Laboratories Ltd | Equity | ₹21.73 Cr | 7.31% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹21.16 Cr | 7.12% |
| Dr Reddy's Laboratories Ltd | Equity | ₹19.07 Cr | 6.42% |
| Cipla Ltd | Equity | ₹18.74 Cr | 6.31% |
| Triparty Repo Trp_010126 | Cash - Repurchase Agreement | ₹18.04 Cr | 6.07% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹14.56 Cr | 4.90% |
| Mankind Pharma Ltd | Equity | ₹11.42 Cr | 3.84% |
| Lupin Ltd | Equity | ₹9.49 Cr | 3.19% |
| Ajanta Pharma Ltd | Equity | ₹9 Cr | 3.03% |
| Dr. Lal PathLabs Ltd | Equity | ₹8.6 Cr | 2.89% |
| Syngene International Ltd | Equity | ₹8.46 Cr | 2.85% |
| Global Health Ltd | Equity | ₹8.3 Cr | 2.79% |
| Aurobindo Pharma Ltd | Equity | ₹7.1 Cr | 2.39% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹6.11 Cr | 2.05% |
| Rainbow Childrens Medicare Ltd | Equity | ₹5.94 Cr | 2.00% |
| Sai Life Sciences Ltd | Equity | ₹5.45 Cr | 1.83% |
| Pfizer Ltd | Equity | ₹4.99 Cr | 1.68% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹4.95 Cr | 1.66% |
| Abbott India Ltd | Equity | ₹4.93 Cr | 1.66% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹4.56 Cr | 1.54% |
| Sanofi India Ltd | Equity | ₹4.09 Cr | 1.38% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹3.7 Cr | 1.25% |
| Shilpa Medicare Ltd | Equity | ₹3.69 Cr | 1.24% |
| Medi Assist Healthcare Services Ltd | Equity | ₹3.68 Cr | 1.24% |
| Star Health and Allied Insurance Co Ltd | Equity | ₹3.64 Cr | 1.22% |
| OneSource Specialty Pharma Ltd | Equity | ₹3.62 Cr | 1.22% |
| Jubilant Pharmova Ltd | Equity | ₹3.22 Cr | 1.08% |
| HealthCare Global Enterprises Ltd | Equity | ₹2.74 Cr | 0.92% |
| Concord Biotech Ltd | Equity | ₹2.69 Cr | 0.91% |
| Cohance Lifesciences Ltd | Equity | ₹2.64 Cr | 0.89% |
| Orchid Pharma Ltd | Equity | ₹1.82 Cr | 0.61% |
| Net Current Assets | Cash | ₹-1.7 Cr | 0.57% |
| Blue Jet Healthcare Ltd | Equity | ₹1.59 Cr | 0.54% |
| Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0.11 Cr | 0.04% |
Large Cap Stocks
43.66%
Mid Cap Stocks
17.60%
Small Cap Stocks
33.21%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹277.1 Cr | 93.24% |
| Financial Services | ₹3.64 Cr | 1.22% |
Standard Deviation
This fund
--
Cat. avg.
16.18%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.91
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.60
Higher the better

Since November 2025
Since November 2025
Since November 2025
Since November 2025
ISIN INF194KB1KF5 | Expense Ratio 0.65% | Exit Load No Charges | Fund Size ₹297 Cr | Age 2 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹1,95,394 Cr
Address
6th Floor, 841, One World Center, Mumbai, 400013
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments